WO2024057238A1 - Single tube sample preparation and calibration for both screening and quantification of analytes - Google Patents
Single tube sample preparation and calibration for both screening and quantification of analytes Download PDFInfo
- Publication number
- WO2024057238A1 WO2024057238A1 PCT/IB2023/059103 IB2023059103W WO2024057238A1 WO 2024057238 A1 WO2024057238 A1 WO 2024057238A1 IB 2023059103 W IB2023059103 W IB 2023059103W WO 2024057238 A1 WO2024057238 A1 WO 2024057238A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alternatively
- ion
- magnetic beads
- isotopic
- sample
- Prior art date
Links
- 238000012216 screening Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 6
- 238000011002 quantification Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 85
- 239000012491 analyte Substances 0.000 claims abstract description 62
- 238000004458 analytical method Methods 0.000 claims abstract description 40
- 238000011088 calibration curve Methods 0.000 claims abstract description 28
- 230000007704 transition Effects 0.000 claims description 119
- 239000011324 bead Substances 0.000 claims description 115
- 230000000155 isotopic effect Effects 0.000 claims description 96
- 230000005291 magnetic effect Effects 0.000 claims description 94
- 239000000523 sample Substances 0.000 claims description 90
- 239000011541 reaction mixture Substances 0.000 claims description 25
- 229960002428 fentanyl Drugs 0.000 claims description 17
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 17
- 239000012071 phase Substances 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 229940088598 enzyme Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 230000005294 ferromagnetic effect Effects 0.000 claims description 11
- 238000004949 mass spectrometry Methods 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- PMCBDBWCQQBSRJ-UHFFFAOYSA-N norfentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C1CCNCC1 PMCBDBWCQQBSRJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 230000005298 paramagnetic effect Effects 0.000 claims description 9
- -1 cyanopropyl Chemical group 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 238000005040 ion trap Methods 0.000 claims description 7
- 238000004811 liquid chromatography Methods 0.000 claims description 7
- 238000010606 normalization Methods 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 238000005342 ion exchange Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 229940049706 benzodiazepine Drugs 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 239000004081 narcotic agent Substances 0.000 claims description 4
- 229940005483 opioid analgesics Drugs 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims description 3
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 3
- 108010060309 Glucuronidase Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 229940125717 barbiturate Drugs 0.000 claims description 3
- 150000001557 benzodiazepines Chemical class 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 125000006267 biphenyl group Chemical group 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000004401 flow injection analysis Methods 0.000 claims description 3
- 229960002870 gabapentin Drugs 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 3
- 229960001797 methadone Drugs 0.000 claims description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims description 3
- 230000006920 protein precipitation Effects 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000001819 mass spectrum Methods 0.000 claims description 2
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 claims 1
- 150000002500 ions Chemical class 0.000 description 124
- 239000000047 product Substances 0.000 description 54
- 125000004429 atom Chemical group 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 201000009032 substance abuse Diseases 0.000 description 9
- 238000002552 multiple reaction monitoring Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 6
- 239000006249 magnetic particle Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- PJMPHNIQZUBGLI-SCUSKTIWSA-N n-(2,3,4,5,6-pentadeuteriophenyl)-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1N(C(=O)CC)C1CCN(CCC=2C=CC=CC=2)CC1 PJMPHNIQZUBGLI-SCUSKTIWSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000009535 clinical urine test Methods 0.000 description 2
- 238000001211 electron capture detection Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- VEXZGXHMUGYJMC-IGMARMGPSA-N chlorine-35 Chemical compound [35ClH] VEXZGXHMUGYJMC-IGMARMGPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940066734 peptide hydrolases Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
Definitions
- Analytical samples can often provide critical analytical information.
- compounds of a related group i.e., drugs and metabolites, hormones in a pathway, biomarkers, and/or peptides from a particular biologic drug
- compounds of a related group i.e., drugs and metabolites, hormones in a pathway, biomarkers, and/or peptides from a particular biologic drug
- a screen is positive, a definitive, quantitative test is then performed to produce a reliably accurate result for a given sample.
- this requires that the original analytical sample be access and processed a second time, requiring additional labor, sample preparation reagents, and involves multiple steps to create an external calibration curve.
- the inventors have recognized the need to combine multiple operations into a single sample reaction tube. This allows for screening and definitive testing in a single injection and provides for a more accurate screening test compared to traditional screen tests due to the presence of an internal calibration curve with an internal standard.
- One aspect of the disclosure includes a method for quantifying at least one analyte in a sample by mass analysis, the method including adding a sample comprising an analyte of interest to a reaction mixture, the reaction mixture comprising at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, ionizing the resulting mixture, monitoring, by mass spectrometry, at least one parent ion and/or at least one fragment ion of the analyte of interest, the first labeled isotopologue and/or the second labeled isotopologue, wherein the at least one fragment ion is selected from the group including a product ion, an isotopic ion, a product ion transition, and an isotopic ion transition; normalizing using the first labeled isotopologue; determining intensity and/or using natural isotopic abundance of the parent and at least one fragment of the second labeled
- the reaction mixture includes at least a third labeled isotopologue, alternatively at least a fourth labeled isotopologue, alternatively at least a fifth labeled isotopologue.
- the second labeled isotopologue, third labeled isotopologue, fourth labeled isotopologue, and/or fifth labeled isotopologue is used to generate an internal calibration curve.
- the first labeled isotopologue and second labeled isotopologue are labeled with at least one isotopic atom.
- the at least one isotopic atom is deuterium, carbon-13, nitrogen-15, or oxygen-18.
- the isotopic atom of the first labeled isotopologue and the isotopic atom of the second labeled isotopologue are different.
- the normalization with first labeled isotopologue further includes using peak area of the parent or product ion of the first labeled isotopologue and peak area of the parent or product ion of the analyte and/or the second labeled isotopologue to calculate a peak area ratio, and normalizing the analyte and/or the second labeled isotopologue using said peak area ratio.
- the product ion transition has an intensity and/or abundance of about 100%.
- the product ion transition is the most intense and/or abundant isotope of the at least one analyte.
- the intensity and/or abundance of the isotopic ion transition is less than about 100%, alternatively less than about 50%, alternatively less than about 25%, alternatively less than about 15%, alternatively less than about 10%, alternatively less than about 5% than a precursor and/or the product ion transition.
- determining the intensity and/or abundance of the at least one product ion transition and/or isotopic ion transition comprises obtaining mass spectrum data corresponding to the at least one product ion transition and/or isotopic ion transition.
- At least two analytes are quantified, alternatively at least three analytes are quantified, alternatively at least four analytes are quantified, alternatively at least five analytes are quantified, alternatively at least six analytes are quantified, alternatively at least seven analytes are quantified, alternatively at least eight analytes are quantified, alternatively at least nine analytes are quantified, alternatively at least ten analytes are quantified.
- At least two product ion transitions are monitored, alternatively at least three product ion transitions are monitored, alternatively at least four product ion transitions are monitored, alternatively at least five product ion transitions are monitored, alternatively at least six product ion transitions are monitored, alternatively at least seven product ion transitions are monitored, alternatively at least eight product ion transitions are monitored, alternatively at least nine product ion transitions are monitored, alternatively at least ten product ion transitions are monitored.
- the intensity difference between the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are used as a response factor for signal intensity normalization.
- the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are at the same concentration.
- At least two isotopic ion transitions are monitored, alternatively at least three isotopic ion transitions are monitored, alternatively at least four isotopic ion transitions are monitored, alternatively at least five isotopic ion transitions are monitored, alternatively at least six isotopic ion transitions are monitored, alternatively at least seven isotopic ion transitions are monitored, alternatively at least eight isotopic ion transitions are monitored, alternatively at least nine isotopic ion transitions are monitored, alternatively at least ten isotopic ion transitions are monitored.
- the method further includes using the intensity and/or abundance of the at least one product ion transition and/or the at least one isotopic ion transition of the second labeled isotopologue to calculate a ratio of the at least one product ion transition and/or the at least one isotopic ion transition to the product and/or precursor, and using the calculated ratio to calculate an isotopic dilution factor (IDF), wherein the IDF is used as a multiplier to compensate for high concentrations of analyte of interest.
- IDF isotopic dilution factor
- the reaction mixture further comprises magnetic beads.
- the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
- the mixed-phase magnetic beads are selected from C4 magnetic beads, C8 magnetic beads, C12 magnetic beads, Cl 8 magnetic beads, cyanopropyl magnetic beads, phenyl magnetic beads, diphenyl magnetic beads, and combinations thereof.
- the sample is desalted using the mixed-phase magnetic beads.
- the enzyme-conjugated magnetic beads are conjugated with trypsin, chymotrypsin, glucuronidase, or combinations thereof.
- the sample is digested and/or hydrolyzed using the enzyme-conjugated magnetic beads.
- the sample is eluted from the magnetic beads prior to being ionized.
- the mass spectrometry is conducted using a mass analyzer.
- the mass analyzer is coupled to a sample introduction device.
- the sample introduction device comprises an acoustic droplet ejector (ADE), a solid phase extraction system, liquid-liquid extraction, protein precipitation, a liquid aspiration system, a microinjector, a nanoinjector, an inkjet printer nozzle, a chromatography instrument, microflow system, solid phase extraction system, differential mobility spectrometer, a trap-and-elute workflow, an open port interface, or direct flow injection.
- ADE acoustic droplet ejector
- the sample introduction device comprises an acoustic droplet ejector (ADE), a solid phase extraction system, liquid-liquid extraction, protein precipitation, a liquid aspiration system, a microinjector, a nanoinjector, an inkjet printer nozzle, a chromatography instrument, microflow system, solid phase extraction system, differential mobility spectrometer, a trap-and-e
- the sample introduction comprises acoustically ejecting the liquid sample into a mobile phase at an open port interface (OPI) using the acoustic droplet ejector (ADE).
- the chromatography instrument is a high performance liquid chromatography (HPLC) instrument, an ultra high performance liquid chromatography instrument (UPLC), Micro liquid chromatography, or Nano liquid chromatography.
- the mass analyzer is configured to perform a first mass analysis on the sample, wherein the first mass analysis is mass screening for an analyte of interest in the sample, and wherein if the analyte of interest is detected in the sample, the mass analyzer is configured to perform a second mass analysis, wherein the second mass analysis is a quantitative analysis.
- the mass analyzer is a tandem mass spectrometer.
- the first mass analysis is performed using a first mass analyzer and the second mass analysis is performed using a second mass analyzer.
- the first mass analyzer is a single-stage mass spectrometer or a tandem mass spectrometer.
- the single-stage mass spectrometer is selected from the group consisting of magnetic sector, quadrupole, time-of-flight (TOF), and ion traps.
- the second mass analyzer is a tandem mass spectrometer.
- the tandem mass spectrometer is selected from the group consisting of a triple quadrupole, a quadrupole-linear ion trap, a quadrupole TOF, and a TOF-TOF.
- the sample is a biological sample.
- the biological sample is selected from the group consisting of urine, blood, oral fluid, plasma, tissue, bone marrow, and tumor samples.
- the method is used in a clinical analysis workflow.
- the clinical analysis is used to screen for drugs of abuse, peptide markers for disease states, and/or peptides from proteins and/or analytes of interest.
- the drugs of abuse are selected from the group consisting of amphetamines, methamphetamines, benzodiazepines, barbiturates, marijuana, cocaine, PCP, methadone, opioids (narcotics), fentanyl, norfentanyl, gabapentin, and pregabalin.
- kits for quantifying at least one analyte in a sample by mass analysis including at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, and magnetic beads.
- the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand- conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
- the kit comprises mixed-phase magnetic beads, enzyme-conjugated magnetic beads and ferromagnetic beads.
- the first labeled isotopologue, second labeled isotopologue and magnetic beads are in a single reaction mixture.
- the single reaction mixture is added to a sample comprising an analyte to be quantified.
- FIGs. 1A-1C depict structures of different isotopologues of fentanyl.
- FIG. 2 depicts an internal isotopic calibration curve according to an aspect of the disclosure.
- FIG. 3 depicts the peak intensities of an analyte of interest, an internal standard (a first labeled isotopologue), and high, middle, and low isotopic calibrants (generated from a second labeled isotopologue) according to an aspect of the disclosure.
- FIG. 4 depicts a single reaction mixture according to an aspect of the disclosure.
- FIG. 5 shows isotopic MRMs for fentanyl-d5 and norfentanyl-d5 selected to generate a calibration curve according to an aspect of the disclosure.
- FIG. 6 shows the samples with known concentrations of fentanyl and norfentanyl analyzed using acoustic ejection mass spectrometry with isotopologues for the internal standard and an internal calibration curve according to an aspect of the disclosure.
- FIG. 7 shows semi-quantitative results for samples with known concentrations of fentanyl and norfentanyl analyzed using acoustic ejection mass spectrometry with isotopologues for the internal standard and an internal calibration curve according to an aspect of the disclosure.
- FIG. 8 shows the reproducibility for an internal standard isotopologue according to an aspect of the disclosure.
- FIG. 9 shows the reproducibility of an internal calibration isotopologue according to an aspect of the disclosure.
- FIGs. 10A and 10B depicts a method comparison for fentanyl between AMES and LC- MS/MS.
- FIGs. 11 A - 11C depicts samples analyzed using AEMS and LC-MS/MS according to an aspect of the disclosure.
- x, y, and/or z means any element of the seven-element set ⁇ (x), (y), (z), (x, y), (x, z), (y, z), (x, y, z) ⁇ .
- x, y and/or z means “one or more of x, y and z”.
- the sample may be a biological sample.
- Biological samples may be biological fluids, which may include, but are not limited to, blood, plasma, serum, oral fluid, or other bodily fluids or excretions, such as but not limited to saliva, urine, cerebrospinal fluid, lacrimal fluid, perspiration, gastrointestinal fluid, amniotic fluid, mucosal fluid, pleural fluid, sebaceous oil, exhaled breath, and the like.
- the biological sample may also be tissue (including tissue biopsies), bone marrow, tumor samples, and other biological samples and materials derived therefrom.
- the sample may also be a chemical sample.
- Chemical samples may include any type of sample including chemicals, including, but not limited to, water samples.
- the sample may also be an environmental sample. Non-limiting examples of environmental samples may include air, soil, and wastes (liquids, solids or sludges).
- the sample may also be a food sample and the food sample may be solid, semisolid, viscous, or liquid.
- the food sample may also be used to test for food safety, including microbial or bacterial analysis.
- the sample may also be dissolved in solvent.
- the solvent may be a liquid, a solid, a gas, or a supercritical fluid.
- the solvent may be a polar or non-polar solvent.
- the solvent may be organic solvent.
- the solvent may be water, including deionized water.
- the sample may be mixed with a matrix material. A non-limiting example of a matrix material includes crystalline compounds.
- the sample may also be dissolved into a solution, incorporated into a liquid, or a component in a homogenous system.
- An analyte may include a substance whose presence, absence, or concentration is to be determined according to methods of the present disclosure.
- Typical analytes may include, but are not limited to, organic molecules, hormones (such as thyroid hormones, estradiol, testosterone, progesterone, estrogen), metabolites (such as glucose or ethanol), proteins, lipids, carbohydrates, and sugars, steroids (such as Vitamin D), peptides (such as procalcitonin), nucleic acid segments, biomarkers (pharmaceuticals such as antibiotics, benzodiazepine), drugs (such as immunosuppressant drugs, narcotics, opioids, etc.), molecules with a regulatory effect in enzymatic processes such as promoters, activators, inhibitors, or cofactors, microorganisms (such as viruses (including EBV, HPV, HIV, HCV, HBV, Influenza, Norovirus, Rotavirus, Adenovirus, etc.), bacteria (H.
- aspects of the disclosure can also allow for the simultaneous analysis of multiple analytes in the same class or different classes (e.g., simultaneous analysis of metabolites and proteins).
- the method is used to prepare the sample for clinical analysis.
- the clinical analysis can be used to screen peptide markers for disease states.
- the clinical analysis can also be used to screen for drugs of abuse.
- Non-limiting examples of drugs of abuse include amphetamines, methamphetamines, benzodiazepines, barbiturates, marijuana, cocaine, PCP, methadone, opioids (narcotics), fentanyl, norfentanyl, gabapentin, and pregabalin.
- the clinical analysis is a clinical urine test or a urinalysis, and the analysis is used to screen for drugs of abuse.
- Urine is a common biological sample used in testing for drugs of abuse. A urinalysis or clinical urine test can detect the presence of a drug of abuse after the drug effects have worn off.
- the sample may be added to a reaction mixture.
- the reaction mixture may include a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest.
- An isotopologue is a molecule that differs only in their isotopic composition from the stable compound. Isotopologue have the same chemical formula and bonding arrangement of atoms, but at least one atom has a different number of neutrons than the parent.
- isotopologues of water include the replacement of both hydrogen atoms with deuterium isotopes of hydrogen (e.g., heavy water) and the replacement of oxygen with the oxygen-18 isotope (e.g., heavy oxygen water).
- the first labeled isotopologue and second labeled isotopologue may be labeled with at least one isotopic atom, but depending on the chemical structure, if the analyte of interest has several atoms of the same element, any one (or all) of them can be altered. Any isotopic atom may be used to label the first labeled isotopologue and a second labeled isotopologue including, but not limited to, deuterium, carbon-13, nitrogen-15, or oxygen-18. Also depending on the analysis desired, the isotopic atom of the first labeled isotopologue and the isotopic atom of the second labeled isotopologue are different.
- the reaction mixture may further include a third labeled isotopologue, fourth labeled isotopologue, and/or fifth labeled isotopologue.
- the reaction mixture may further include magnetic beads.
- Magnetic beads or magnetic particles are typically nanoparticles or microparticles that have paramagnetic properties. Magnetic beads or magnetic particles are typically hydrophilic and disperse easily in aqueous solutions. The surface coating and/or chemistry of the magnetic beads or magnetic particles allow various biomolecules such as proteins, peptides, and nucleic acids to bind to the magnetic beads or magnetic particles.
- magnetic separation is employed to the magnetic beads or magnetic particles from a suspension by applying a magnetic force.
- magnetic beads include mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
- Desalting prior to ionization may improve ionization efficiency and may also purify and concentrate the sample.
- the sample may be desalted using mixed-phase magnetic beads, including, but not limited to, C4 magnetic beads, C8 magnetic beads, C12 magnetic beads, Cl 8 magnetic beads, cyanopropyl magnetic beads, phenyl magnetic beads, diphenyl magnetic beads, and combinations thereof.
- C4, C8, Cl 2, or Cl 8 magnetic beads for example, retains nonpolar solutes, such as peptides.
- Enzymatic hydrolysis is a process where peptide bonds in proteins are hydrolyzed using enzymes, such as proteases, peptidases, or peptide hydrolases.
- Proteases can be either exopeptidases, which act near the end of a polypeptide chain and include, for example, aminopeptidases and dipeptidyl peptidases, or endopeptidases, which act on nonterminal peptide bonds and include, for example, serine proteases, cysteine proteases, aspartic acid proteases, and metallo endopeptidases.
- Enzymatic hydrolysis can also include the use of the glycosidase family of enzymes that catalyze the breakdown of complex carbohydrates.
- Suitable hydrolysis enzymes include, but are not limited to, 0-glucuronidase, glucuronidase, trypsin, chymotrypsin, a protease, LysC, LysN, AspN, GluC, ArgC, pronase, pepsin, and prolidase.
- Suitable hydrolysis enzymes also include those capable of hydrolyzing glyosidic linkages, such as those formed during metabolic processes. Ferromagnetic beads, paramagnetic beads, and/or superparamagnetic beads may also be used to stir the reaction mixture and the sample may be eluted from the magnetic beads prior to being ionized.
- the mixture of the sample with the isotopologue may be ionized using an ionization method known in the art.
- ionization methods include chemical ionization (CI), electron impact ionization (El), fast atom bombardment (FAB), electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), laser ionization (LIMS), matrix assisted laser desorption ionization (MALDI), plasma-desorption ionization (PD), resonance ionization (RIMS), secondary ionization (SIMS), and thermal ionization (UMS).
- CI chemical ionization
- El electron impact ionization
- FAB fast atom bombardment
- ESI electrospray ionization
- APCI atmospheric pressure chemical ionization
- LIMS laser ionization
- MALDI matrix assisted laser desorption ionization
- PD plasma-desorption ionization
- RIMS resonance ionization
- SIMS secondary i
- the method further includes monitoring, by mass spectrometry, at least one parent or product ion of the analyte of interest and at least one isotopic ion transition for the first labeled isotopologue and the second labeled isotopologue.
- the monitoring of the product ion transition and/or isotopic ion transition for the at least one analyte may also include monitoring an isotopic abundance for at least one ion pair of the at least one analyte.
- m/z mass-to-charge ratio
- two analytes are quantified, alternatively at least three analytes are quantified, alternatively at least four analytes are quantified, alternatively at least five analytes are quantified, alternatively at least six analytes are quantified, alternatively at least seven analytes are quantified, alternatively at least eight analytes are quantified, alternatively at least nine analytes are quantified, alternatively at least ten analytes are quantified.
- Product ion transition monitoring is a technique in which the m/z range of a first mass separator is specifically selected to transmit a molecular ion (often referred to as “the parent ion” or “the precursor ion”) to an ion fragmentor to produce fragment ions (often referred to as “daughter ions” or “product ion”).
- the transmitted m/z range of a second mass separator is selected to transmit one or more product ions to a detector that measures the product ion signal.
- the observed m/z ratio (and may also referred to as “mass data”) of a parent (or precursor) ion and its corresponding product (or daughter) ion is a product ion transition.
- This ion transition may also be referred to as a precursor-product ion transition or a product-daughter ion transition.
- MRM multiple reaction monitoring
- two or more transitions are monitored, each corresponding to a different fragment or product ion.
- the parent ion of morphine is 286, and the most intense ions created by the fragmentation of 286 are 201, 181, and 165.
- the three product ion transitions for morphine are 286 —> 201, 286 —> 181, and 286 — ⁇ 165.
- At least two product ion transitions are monitored, alternatively at least three product ion transitions are monitored, alternatively at least four product ion transitions are monitored, alternatively at least five product ion transitions are monitored, alternatively at least six product ion transitions are monitored, alternatively at least seven product ion transitions are monitored, alternatively at least eight product ion transitions are monitored, alternatively at least nine product ion transitions are monitored, alternatively at least ten product ion transitions are monitored.
- the product ion has an intensity and/or abundance of about 100%.
- the product ion is the most intense and/or abundant isotope of the at least one analyte.
- Isotopic MRM isotopic multiple reaction monitoring
- the workflow utilizes the ion transitions based on the natural isotopic abundance of analytes.
- This ion transition may also be referred to as a precursor-isotopic ion transition or isotopic ion transition.
- there are two stable isotopes of chlorine chlorine 35 (75.8 % natural abundance) and chlorine 37 (24.2 % natural abundance).
- each natural isotopic ion’s relative abundance value is different from another in a proportionally decreasing fashion.
- the intensity and/or abundance of the isotopic ion is less than about 100%, alternatively less than about 50%, alternatively less than about 25%, alternatively less than about 15%, alternatively less than about 10%, alternatively less than about 5% than a precursor and/or the product ion.
- the natural isotopic daughter ion acts as an internal standard, allowing for quantification of the analyte without requiring the addition of a calibrant or stable-isotope labeled analyte.
- At least two isotopic ion transitions are monitored, alternatively at least three isotopic ion transitions are monitored, alternatively at least four isotopic ion transitions are monitored, alternatively at least five isotopic ion transitions are monitored, alternatively at least six isotopic ion transitions are monitored, alternatively at least seven isotopic ion transitions are monitored, alternatively at least eight isotopic ion transitions are monitored, alternatively at least nine isotopic ion transitions are monitored, alternatively at least ten isotopic ion transitions are monitored.
- mass spectrometers single-stage mass spectrometers or that have the ability to select and fragment molecular ions
- tandem mass spectrometers i.e., mass spectrometers that have two mass separators with an ion fragmentor disposed in the ion flight path between the two mass separators.
- mass separators include, but are not limited to, quadrupoles, RF multipoles, ion traps, time-of-flight (TOF), and TOF in conjunction with a timed ion selector.
- Non-limiting examples of ion fragmentors include, but are not limited to, those operating on the principles of collision induced dissociation (CID, also referred to as collisionally assisted dissociation (CAD)), photoinduced dissociation (PID), surface induced dissociation (SID), post source decay, by interaction with an electron beam (e.g., electron induced dissociation (EID), electron capture dissociation (ECD)), interaction with thermal radiation (e.g., thermal/black body infrared radiative dissociation (BIRD)), post source decay, or combinations thereof.
- CID collisionally assisted dissociation
- PID photoinduced dissociation
- SID surface induced dissociation
- post source decay by interaction with an electron beam (e.g., electron induced dissociation (EID), electron capture dissociation (ECD)), interaction with thermal radiation (e.g., thermal/black body infrared radiative dissociation (BIRD)), post source decay, or combinations thereof.
- Non-limiting examples of a single-stage mass spectrometry system includes magnetic sector, quadrupole, time-of-flight (TOF), and ion traps.
- Non-limiting examples of tandem mass spectrometry systems for mass analysis include, but are not limited to, those which comprise one or more of a triple quadrupole, a quadrupole-linear ion trap (e.g., QTRAP® System), a quadrupole TOF (e.g., TripleTOF® System), and a TOF-TOF.
- a mass analyzer is configured to perform a first mass analysis on the sample, wherein the first mass analysis is mass screening for an analyte of interest in the sample, and wherein if the analyte of interest is detected in the sample, the mass analyzer is configured to perform a second mass analysis, wherein the second mass analysis is a quantitative analysis.
- the sample may be transferred from the sample introduction device to the mass analyzer using transfer techniques generally known in the art such as, for example, techniques including a microinjector, a nano injector, an inkjet printer nozzle, an acoustic droplet ejector (ADE), a solid phase extraction system, or a liquid aspiration system. While the transferred volumes may vary, typical volumes of transferred solutions fall within a range of about 2.5 nL to about 500 nL.
- Non-limiting examples of the sample introduction device include a chromatography instrument (such as a high performance liquid chromatography (HPLC) instrument, an ultra high performance liquid chromatography instrument (UPLC), micro liquid chromatography, or nano liquid chromatography), microflow system, solid-phase extraction system, liquid-liquid extraction, protein precipitation, differential mobility spectrometer, a trap-and-elute workflow, an open port interface, or direct flow injection.
- the sample solution may be introduced to the ion source by acoustically ejecting the sample into a mobile phase at an open port interface (OPI) using the acoustic droplet ejector (ADE).
- acoustic ejection mass spectrometry AEMS
- acoustic ejection mass spectrometry systems for qualitative mass analysis include an Echo® MS System.
- any number of additional elements can be included in the sample processing system including, for example, an ion mobility spectrometer (e.g., a differential mobility spectrometer for ion selection) that is disposed between the ionization chamber and the mass analyzer and is configured to separate ions based on their mobility through a drift gas in high- and low-fields rather than their mass-to-charge ratio.
- the mass analyzer can comprise a detector that can detect the ions which pass through the mass analyzer and can, for example, supply a signal indicative of the number of ions per second that are detected.
- the first labeled isotopologue is an internal standard that is used for normalization.
- normalization with first labeled isotopologue includes using the peak area of the parent or product ion of the first labeled isotopologue and the peak area of the parent or product ion of the analyte and/or the second labeled isotopologue to calculate a peak area ratio. The analyte and/or the second labeled isotopologue is then normalized using said peak area ratio.
- the intensity difference between the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest may be used as a response factor for signal intensity normalization.
- the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest may be at the same concentration.
- the second labeled isotopologue (and any subsequent labeled isotopologue) may be used for the generation an internal calibration curve.
- the intensity, or area, of a product ion transition or isotopic ion transition depends on several factors including concentration, ease of ionization, and fragmentation efficiency.
- the peak areas for product ion transitions or isotopic ion transitions are integrated as measures of product ion or isotopic ion abundance and serve as the basis for quantitative comparisons.
- the signal intensity or relative abundance of the product ion and/or isotopic ion is compared to, for example, an internal calibration curve constructed using one or more labeled isotopologues and/or by calculating a ratio of at least one isotopic ion transition to the corresponding analyte, and quantifying the amount of the analyte in the sample using the calculated ratio.
- the calibration curve may be generated using at least one product ion transition, at least one isotopic ion transition, or a combination of both.
- the internal calibration curve may be constructed by using the natural isotopic abundance of one isotopologue, by using multiple differently labeled isotopologues of different concentrations, or combinations of these methods.
- FIGs. 1A-1C depict structures of different isotopologues of fentanyl.
- the unlabeled fentanyl is used to quantify the unknowns and either of the isotopologues could be used for an internal standard.
- FIG. 2 depicts an internal isotopic calibration curve according to an aspect of the disclosure.
- FIG. 3 depicts the peak intensities of an analyte of interest, an internal standard (a first labeled isotopologue), and high, middle, and low isotopic calibrants (generated from a second labeled isotopologue) according to an aspect of the disclosure.
- the calculated ratio may be used to calculate an isotopic dilution factor (“IDF”).
- IDF isotopic dilution factor
- This IDF may be used as a multiplier to compensate for abundance differences between the naturally occurring abundant isotopes and the corresponding analyte and/or precursor.
- the precursor is most abundant isotope.
- the isotope MRM conditions may be auto- optimized. For example, the theoretical isotope intensity ratio of both precursor and isotopic ions, and the desired intensity level is used to choose the isotope MRM conditions.
- the most abundant transition peak is the peak that is used to quantify the majority of the samples.
- the isotopic ion transition peak is a peak of lower abundance that can be used as a dilution factor.
- the factor difference between the quantifying transition and isotopic ion transition can be easily determined and applied to samples which require quantification using the isotopic ion transition.
- sample preparation be performed in under 10 minutes, alternatively under 9 minutes, alternatively under 8 minutes, alternatively under 7 minutes, alternatively under 6 minutes, alternatively under 5 minutes, alternatively under 4 minutes, alternatively under 3 minutes, alternatively under 2 minutes, or alternatively under 1 minute.
- the resulting sample preparation product can be used for both screening and definitive testing.
- the disclosed methods allow for simple sample preparation that can be performed manually (point of care application) or with automation (for large batches). Due to the presence of an internal calibration curve with an internal standard in the reagent, the screening test can now be classified as a semi-quantitative test which provides a user with a greater level of knowledge about each individual sample before the sample is quantitatively analyzed on the definitive testing platform.
- the combination of internal calibration curve and internal standard for each individual sample ensures that matrix effects are neutralized. Comparing results from an unknown sample to an external calibration curve can often ignore sample matrix effects.
- the use of the reaction mixture reduces matrix effects and at the same time desalts the sample.
- the use of internal calibration enables random access testing, enabling emergency testing and point of care testing with a mass spectrometer.
- kits included for carrying out the disclosed methods may include at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest and magnetic beads.
- the magnetic beads may include, but are not limited to, the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
- the first labeled isotopologue, second labeled isotopologue and magnetic beads are in a single reaction mixture. As shown in FIG.
- the reaction mixture includes the first labeled isotopologue, second labeled isotopologue, ferromagnetic beads, and desalting beads.
- the single reaction mixture may also be housed in a container.
- suitable contains include, test tubes, centrifuge tubes, vials, cups, or bottles.
- the container is a sample plate, the sample plate comprising a plurality of sample wells.
- the sample wells may contain the sample which the reaction mixture is added to. Depending on the analysis desired, the sample wells may contain several different samples and/or calibrants.
- Urine samples can be collected according to the SAMHSA guidelines (Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention), available at https://www.samhsa.gov/sites/default/files/specimen-collection-handbook-2014.pdf. Urine specimens are typically submitted to certified laboratories within 24 hours after collection.
- 50 pL of the reaction mixture was added to 50 pL of the sample. Electromagnets were used to mix the sample mixture and a magnetic rack is used to pull the magnetic beads with to one side of the reaction vessel. The supernatant was removed and the magnetic beads were washed with 200 pL of di water and 65 pL to elute the desalted sample. Electromagnets were used to mix the sample mixture and a magnetic rack is used to pull the magnetic beads with to one side of the reaction vessel. 50 pL was the supernatant and 10 pL of water were added to an acoustic ejection mass spectrometry (AMES) 384- well plate. The plate was then shook on a planar rotator.
- AMES acoustic ejection mass spectrometry
- the MRM transitions for fentanyl monitored were 327.25 — 188.14 (analyte of interest); 343.2 — 105.1 (internal standard); and 342.24 — 188.14, 343.25 —> 189.15, and 344.24 — > 190.15 (calibration curve).
- the MRM transitions for norfentanyl monitored were 233.16 — 84.08 (analyte of interest); 239.1 — 156.1 (internal standard); and 238.18 — 84.08, 240.18 — 84.08, and 240.18 —>85.08 (calibration curve).
- the peak areas for the three isotopic MRMs for fentanyl and norfentanyl were corrected with a response factor adjustment derived from the respective internals standards. These isotopic MRMs were also chosen so that they do not interfere with the internal standard.
- FIG. 10A and 10B show A method comparison for fentanyl between the AEMS method and an LC-MS/MS reference method. In general, there was a positive correlation between the two methods, however, the correlation coefficient is relatively low. Additionally, FIG. 10B shows the percent difference chart for the comparison between the AEMS method and LC-MS/MS reference method. The results shown in FIG. 10A and FIG.
- FIG. 11 A shows fentanyl and norfentanyl isotopic MRMs separated from one another while FIG. 1 IB and FIG. 11C show the detailed information of each isotopic MRM for norfentanyl (FIG. 1 IB) and fentanyl (FIG. 11C).
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The presently claims and described technology provides methods and kits for quantifying at least one analyte in a sample by mass analysis using a labeled isotopologues as an internal standards and to generate internal calibration curves.
Description
SINGLE TUBE SAMPLE PREPARATION AND CALIBRATION FOR BOTH SCREENING
AND QUANTIFICATION OF ANALYTES
RELATED APPLICATIONS
[001] The present patent application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 63/407,514, filed September 16, 2022, the content of which is hereby incorporated by reference in its entirety into this disclosure.
BACKGROUND
[002] Analytical samples, including biological samples and bodily liquids, can often provide critical analytical information. Presently, compounds of a related group (i.e., drugs and metabolites, hormones in a pathway, biomarkers, and/or peptides from a particular biologic drug) are generally screened for the presence of an analyte of interest and, if a screen is positive, a definitive, quantitative test is then performed to produce a reliably accurate result for a given sample. However, this requires that the original analytical sample be access and processed a second time, requiring additional labor, sample preparation reagents, and involves multiple steps to create an external calibration curve.
SUMMARY
[003] The inventors have recognized the need to combine multiple operations into a single sample reaction tube. This allows for screening and definitive testing in a single injection and provides for a more accurate screening test compared to traditional screen tests due to the presence of an internal calibration curve with an internal standard.
[004] One aspect of the disclosure includes a method for quantifying at least one analyte in a sample by mass analysis, the method including adding a sample comprising an analyte of interest to a reaction mixture, the reaction mixture comprising at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, ionizing the resulting mixture, monitoring, by mass spectrometry, at least one parent ion and/or at least one fragment ion of the
analyte of interest, the first labeled isotopologue and/or the second labeled isotopologue, wherein the at least one fragment ion is selected from the group including a product ion, an isotopic ion, a product ion transition, and an isotopic ion transition; normalizing using the first labeled isotopologue; determining intensity and/or using natural isotopic abundance of the parent and at least one fragment of the second labeled isotopologue; generating an internal calibration curve based at least one product ion transition and/or at least one isotopic ion transition of the second labeled isotopologue; and quantifying the at least one analyte present in the sample using the calibration curve.
[005] In some aspects, the reaction mixture includes at least a third labeled isotopologue, alternatively at least a fourth labeled isotopologue, alternatively at least a fifth labeled isotopologue. In another aspect, the second labeled isotopologue, third labeled isotopologue, fourth labeled isotopologue, and/or fifth labeled isotopologue is used to generate an internal calibration curve.
[006] In some aspects, the first labeled isotopologue and second labeled isotopologue are labeled with at least one isotopic atom. In another aspect, the at least one isotopic atom is deuterium, carbon-13, nitrogen-15, or oxygen-18. In yet a further aspect, the isotopic atom of the first labeled isotopologue and the isotopic atom of the second labeled isotopologue are different.
[007] In some aspect, the normalization with first labeled isotopologue further includes using peak area of the parent or product ion of the first labeled isotopologue and peak area of the parent or product ion of the analyte and/or the second labeled isotopologue to calculate a peak area ratio, and normalizing the analyte and/or the second labeled isotopologue using said peak area ratio.
[008] In some aspects, the product ion transition has an intensity and/or abundance of about 100%. In another aspect, the product ion transition is the most intense and/or abundant isotope of the at least one analyte. In some aspects, the intensity and/or abundance of the isotopic ion transition is less than about 100%, alternatively less than about 50%, alternatively less than about 25%, alternatively less than about 15%, alternatively less than about 10%, alternatively less than about 5% than a precursor and/or the product ion transition. In some aspects, determining the intensity and/or abundance of the at least one product ion transition and/or isotopic ion transition
comprises obtaining mass spectrum data corresponding to the at least one product ion transition and/or isotopic ion transition.
[009] In some aspects, at least two analytes are quantified, alternatively at least three analytes are quantified, alternatively at least four analytes are quantified, alternatively at least five analytes are quantified, alternatively at least six analytes are quantified, alternatively at least seven analytes are quantified, alternatively at least eight analytes are quantified, alternatively at least nine analytes are quantified, alternatively at least ten analytes are quantified.
[010] In some aspects, at least two product ion transitions are monitored, alternatively at least three product ion transitions are monitored, alternatively at least four product ion transitions are monitored, alternatively at least five product ion transitions are monitored, alternatively at least six product ion transitions are monitored, alternatively at least seven product ion transitions are monitored, alternatively at least eight product ion transitions are monitored, alternatively at least nine product ion transitions are monitored, alternatively at least ten product ion transitions are monitored.
[Oi l] In an aspect, the intensity difference between the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are used as a response factor for signal intensity normalization. In another aspect, the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are at the same concentration.
[012] In some aspects, at least two isotopic ion transitions are monitored, alternatively at least three isotopic ion transitions are monitored, alternatively at least four isotopic ion transitions are monitored, alternatively at least five isotopic ion transitions are monitored, alternatively at least six isotopic ion transitions are monitored, alternatively at least seven isotopic ion transitions are monitored, alternatively at least eight isotopic ion transitions are monitored, alternatively at least nine isotopic ion transitions are monitored, alternatively at least ten isotopic ion transitions are monitored.
[013] In some aspects, the method further includes using the intensity and/or abundance of the at least one product ion transition and/or the at least one isotopic ion transition of the second labeled isotopologue to calculate a ratio of the at least one product ion transition and/or the at
least one isotopic ion transition to the product and/or precursor, and using the calculated ratio to calculate an isotopic dilution factor (IDF), wherein the IDF is used as a multiplier to compensate for high concentrations of analyte of interest.
[014] In some aspects, the reaction mixture further comprises magnetic beads. In another aspect, the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof. In a further aspect, the mixed-phase magnetic beads are selected from C4 magnetic beads, C8 magnetic beads, C12 magnetic beads, Cl 8 magnetic beads, cyanopropyl magnetic beads, phenyl magnetic beads, diphenyl magnetic beads, and combinations thereof. In yet another aspect, the sample is desalted using the mixed-phase magnetic beads. In another aspect, the enzyme-conjugated magnetic beads are conjugated with trypsin, chymotrypsin, glucuronidase, or combinations thereof. In a further aspect, the sample is digested and/or hydrolyzed using the enzyme-conjugated magnetic beads. In yet another aspect, the sample is eluted from the magnetic beads prior to being ionized.
[015] In an aspect, the mass spectrometry is conducted using a mass analyzer. In another aspect, the mass analyzer is coupled to a sample introduction device. In a further aspect, the sample introduction device comprises an acoustic droplet ejector (ADE), a solid phase extraction system, liquid-liquid extraction, protein precipitation, a liquid aspiration system, a microinjector, a nanoinjector, an inkjet printer nozzle, a chromatography instrument, microflow system, solid phase extraction system, differential mobility spectrometer, a trap-and-elute workflow, an open port interface, or direct flow injection. In another aspect, the sample introduction comprises acoustically ejecting the liquid sample into a mobile phase at an open port interface (OPI) using the acoustic droplet ejector (ADE). In an aspect, the chromatography instrument is a high performance liquid chromatography (HPLC) instrument, an ultra high performance liquid chromatography instrument (UPLC), Micro liquid chromatography, or Nano liquid chromatography.
[016] In an aspect, the mass analyzer is configured to perform a first mass analysis on the sample, wherein the first mass analysis is mass screening for an analyte of interest in the sample,
and wherein if the analyte of interest is detected in the sample, the mass analyzer is configured to perform a second mass analysis, wherein the second mass analysis is a quantitative analysis. In another aspect, the mass analyzer is a tandem mass spectrometer. In a further aspect, the first mass analysis is performed using a first mass analyzer and the second mass analysis is performed using a second mass analyzer.
[017] In an aspect, the first mass analyzer is a single-stage mass spectrometer or a tandem mass spectrometer. In another aspect, the single-stage mass spectrometer is selected from the group consisting of magnetic sector, quadrupole, time-of-flight (TOF), and ion traps.
[018] In an aspect, the second mass analyzer is a tandem mass spectrometer. In another aspect, the tandem mass spectrometer is selected from the group consisting of a triple quadrupole, a quadrupole-linear ion trap, a quadrupole TOF, and a TOF-TOF.
[019] In an aspect, the sample is a biological sample. In another aspect, the biological sample is selected from the group consisting of urine, blood, oral fluid, plasma, tissue, bone marrow, and tumor samples.
[020] In an aspect, the method is used in a clinical analysis workflow. In another aspect, the clinical analysis is used to screen for drugs of abuse, peptide markers for disease states, and/or peptides from proteins and/or analytes of interest. In a further aspect, the drugs of abuse are selected from the group consisting of amphetamines, methamphetamines, benzodiazepines, barbiturates, marijuana, cocaine, PCP, methadone, opioids (narcotics), fentanyl, norfentanyl, gabapentin, and pregabalin.
[021 ] One aspect of the disclosure includes a kit for quantifying at least one analyte in a sample by mass analysis, the kit including at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, and magnetic beads. In an aspect, the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand- conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof. In a further aspect, the kit comprises mixed-phase magnetic beads, enzyme-conjugated magnetic beads and ferromagnetic beads. In yet a further aspect, the first labeled isotopologue, second
labeled isotopologue and magnetic beads are in a single reaction mixture. In still a further aspect, wherein the single reaction mixture is added to a sample comprising an analyte to be quantified.
BRIEF DESCRIPTION OF THE DRAWINGS
[022] Aspects of the present disclosure will now be described, by way of example only, with reference to the attached Figures, wherein:
[023] FIGs. 1A-1C depict structures of different isotopologues of fentanyl.
[024] FIG. 2 depicts an internal isotopic calibration curve according to an aspect of the disclosure.
[025] FIG. 3 depicts the peak intensities of an analyte of interest, an internal standard (a first labeled isotopologue), and high, middle, and low isotopic calibrants (generated from a second labeled isotopologue) according to an aspect of the disclosure.
[026] FIG. 4 depicts a single reaction mixture according to an aspect of the disclosure.
[027] FIG. 5 shows isotopic MRMs for fentanyl-d5 and norfentanyl-d5 selected to generate a calibration curve according to an aspect of the disclosure.
[028] FIG. 6 shows the samples with known concentrations of fentanyl and norfentanyl analyzed using acoustic ejection mass spectrometry with isotopologues for the internal standard and an internal calibration curve according to an aspect of the disclosure.
[029] FIG. 7 shows semi-quantitative results for samples with known concentrations of fentanyl and norfentanyl analyzed using acoustic ejection mass spectrometry with isotopologues for the internal standard and an internal calibration curve according to an aspect of the disclosure.
[030] FIG. 8 shows the reproducibility for an internal standard isotopologue according to an aspect of the disclosure.
[031 ] FIG. 9 shows the reproducibility of an internal calibration isotopologue according to an aspect of the disclosure.
[032] FIGs. 10A and 10B depicts a method comparison for fentanyl between AMES and LC- MS/MS.
[033] FIGs. 11 A - 11C depicts samples analyzed using AEMS and LC-MS/MS according to an aspect of the disclosure.
DETAILED DESCRIPTION
[034] It is to be understood that this disclosure is not limited to the particular methodology, protocols, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to limit the scope of the present disclosure or the appended claims.
[035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods described herein belong.
[036] The singular form "a", “an” and “the” include plural referents unless the context clearly dictates otherwise. These articles refer to one or to more than one (i.e., to at least one). The term “and/or” means any one or more of the items in the list joined by “and/or”. As an example, “x and/or y” means any element of the three-element set {(x), (y), (x, y)}. In other words, “x and/or y” means “one or both of x and y”. As another example, “x, y, and/or z” means any element of the seven-element set {(x), (y), (z), (x, y), (x, z), (y, z), (x, y, z)}. In other words, “x, y and/or z” means “one or more of x, y and z”.
[037] The term “about” as used in connection with a numerical value throughout the specification and the claims denotes an interval of accuracy, familiar and acceptable to a person skilled in the art. In general, such interval of accuracy is +/-10%.
[038] Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[039] The term “exemplary” means serving as a non-limiting example, instance, or illustration. As utilized herein, the terms “e.g.,” and “for example” set off lists of one or more non-limiting aspects, examples, instances, or illustrations.
[040] Aspects of this disclosure include a methods for quantifying at least one analyte in a sample by mass analysis. The sample may be a biological sample. Biological samples may be biological fluids, which may include, but are not limited to, blood, plasma, serum, oral fluid, or other bodily fluids or excretions, such as but not limited to saliva, urine, cerebrospinal fluid, lacrimal fluid, perspiration, gastrointestinal fluid, amniotic fluid, mucosal fluid, pleural fluid, sebaceous oil, exhaled breath, and the like. The biological sample may also be tissue (including tissue biopsies), bone marrow, tumor samples, and other biological samples and materials derived therefrom. The sample may also be a chemical sample. Chemical samples may include any type of sample including chemicals, including, but not limited to, water samples. The sample may also be an environmental sample. Non-limiting examples of environmental samples may include air, soil, and wastes (liquids, solids or sludges). The sample may also be a food sample and the food sample may be solid, semisolid, viscous, or liquid. The food sample may also be used to test for food safety, including microbial or bacterial analysis. The sample may also be dissolved in solvent. The solvent may be a liquid, a solid, a gas, or a supercritical fluid. The solvent may be a polar or non-polar solvent. The solvent may be organic solvent. The solvent may be water, including deionized water. The sample may be mixed with a matrix material. A non-limiting example of a matrix material includes crystalline compounds. The sample may also be dissolved into a solution, incorporated into a liquid, or a component in a homogenous system.
[041] An analyte may include a substance whose presence, absence, or concentration is to be determined according to methods of the present disclosure. Typical analytes may include, but are not limited to, organic molecules, hormones (such as thyroid hormones, estradiol, testosterone, progesterone, estrogen), metabolites (such as glucose or ethanol), proteins, lipids, carbohydrates, and sugars, steroids (such as Vitamin D), peptides (such as procalcitonin), nucleic acid segments, biomarkers (pharmaceuticals such as antibiotics, benzodiazepine), drugs (such as immunosuppressant drugs, narcotics, opioids, etc.), molecules with a regulatory effect in enzymatic processes such as promoters, activators, inhibitors, or cofactors, microorganisms (such as viruses (including EBV, HPV, HIV, HCV, HBV, Influenza, Norovirus, Rotavirus, Adenovirus,
etc.), bacteria (H. pylori, Streptococcus, MRSA, C. diff, Ligionella, etc.), fungus, parasites (plasmodium, etc.), cells, cell components (such as cell membranes), spores, nucleic acids (such as DNA and RNA), etc. Aspects of the disclosure can also allow for the simultaneous analysis of multiple analytes in the same class or different classes (e.g., simultaneous analysis of metabolites and proteins). In an aspect of the disclosure, the method is used to prepare the sample for clinical analysis. The clinical analysis can be used to screen peptide markers for disease states. The clinical analysis can also be used to screen for drugs of abuse. Non-limiting examples of drugs of abuse include amphetamines, methamphetamines, benzodiazepines, barbiturates, marijuana, cocaine, PCP, methadone, opioids (narcotics), fentanyl, norfentanyl, gabapentin, and pregabalin. In an aspect, the clinical analysis is a clinical urine test or a urinalysis, and the analysis is used to screen for drugs of abuse. Urine is a common biological sample used in testing for drugs of abuse. A urinalysis or clinical urine test can detect the presence of a drug of abuse after the drug effects have worn off.
[042] In an aspect, the sample may be added to a reaction mixture. The reaction mixture may include a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest. An isotopologue is a molecule that differs only in their isotopic composition from the stable compound. Isotopologue have the same chemical formula and bonding arrangement of atoms, but at least one atom has a different number of neutrons than the parent. For example, isotopologues of water include the replacement of both hydrogen atoms with deuterium isotopes of hydrogen (e.g., heavy water) and the replacement of oxygen with the oxygen-18 isotope (e.g., heavy oxygen water). The first labeled isotopologue and second labeled isotopologue may be labeled with at least one isotopic atom, but depending on the chemical structure, if the analyte of interest has several atoms of the same element, any one (or all) of them can be altered. Any isotopic atom may be used to label the first labeled isotopologue and a second labeled isotopologue including, but not limited to, deuterium, carbon-13, nitrogen-15, or oxygen-18. Also depending on the analysis desired, the isotopic atom of the first labeled isotopologue and the isotopic atom of the second labeled isotopologue are different. The reaction mixture may further include a third labeled isotopologue, fourth labeled isotopologue, and/or fifth labeled isotopologue.
[043] In an exemplary method, the reaction mixture may further include magnetic beads. Magnetic beads or magnetic particles are typically nanoparticles or microparticles that have paramagnetic properties. Magnetic beads or magnetic particles are typically hydrophilic and disperse easily in aqueous solutions. The surface coating and/or chemistry of the magnetic beads or magnetic particles allow various biomolecules such as proteins, peptides, and nucleic acids to bind to the magnetic beads or magnetic particles. Once a biomolecule of interest is bound to a magnetic bead or magnetic particle, magnetic separation is employed to the magnetic beads or magnetic particles from a suspension by applying a magnetic force. Non-limiting examples of magnetic beads include mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
[044] Desalting prior to ionization may improve ionization efficiency and may also purify and concentrate the sample. The sample may be desalted using mixed-phase magnetic beads, including, but not limited to, C4 magnetic beads, C8 magnetic beads, C12 magnetic beads, Cl 8 magnetic beads, cyanopropyl magnetic beads, phenyl magnetic beads, diphenyl magnetic beads, and combinations thereof. The use of C4, C8, Cl 2, or Cl 8 magnetic beads, for example, retains nonpolar solutes, such as peptides.
[045] Enzymatic hydrolysis is a process where peptide bonds in proteins are hydrolyzed using enzymes, such as proteases, peptidases, or peptide hydrolases. Proteases can be either exopeptidases, which act near the end of a polypeptide chain and include, for example, aminopeptidases and dipeptidyl peptidases, or endopeptidases, which act on nonterminal peptide bonds and include, for example, serine proteases, cysteine proteases, aspartic acid proteases, and metallo endopeptidases. Enzymatic hydrolysis can also include the use of the glycosidase family of enzymes that catalyze the breakdown of complex carbohydrates. Suitable hydrolysis enzymes include, but are not limited to, 0-glucuronidase, glucuronidase, trypsin, chymotrypsin, a protease, LysC, LysN, AspN, GluC, ArgC, pronase, pepsin, and prolidase. Suitable hydrolysis enzymes also include those capable of hydrolyzing glyosidic linkages, such as those formed during metabolic processes. Ferromagnetic beads, paramagnetic beads, and/or superparamagnetic beads may also be used to stir the reaction mixture and the sample may be eluted from the magnetic beads prior to being ionized.
[046] In an exemplary aspect, the mixture of the sample with the isotopologue may be ionized using an ionization method known in the art. Non-limiting ionization methods include chemical ionization (CI), electron impact ionization (El), fast atom bombardment (FAB), electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), laser ionization (LIMS), matrix assisted laser desorption ionization (MALDI), plasma-desorption ionization (PD), resonance ionization (RIMS), secondary ionization (SIMS), and thermal ionization (UMS).
[047] In an aspect, the method further includes monitoring, by mass spectrometry, at least one parent or product ion of the analyte of interest and at least one isotopic ion transition for the first labeled isotopologue and the second labeled isotopologue.
[048] The monitoring of the product ion transition and/or isotopic ion transition for the at least one analyte may also include monitoring an isotopic abundance for at least one ion pair of the at least one analyte. As long as the mass-to-charge ratio (m/z) for the analytes of interest and/or corresponding ion pairs do not overlap, an infinite number of ion pairs can be monitored. This allows for the quantification of multiple analytes in one sample. In exemplary methods, two analytes are quantified, alternatively at least three analytes are quantified, alternatively at least four analytes are quantified, alternatively at least five analytes are quantified, alternatively at least six analytes are quantified, alternatively at least seven analytes are quantified, alternatively at least eight analytes are quantified, alternatively at least nine analytes are quantified, alternatively at least ten analytes are quantified.
[049] Product ion transition monitoring is a technique in which the m/z range of a first mass separator is specifically selected to transmit a molecular ion (often referred to as “the parent ion” or “the precursor ion”) to an ion fragmentor to produce fragment ions (often referred to as “daughter ions” or “product ion”). The transmitted m/z range of a second mass separator is selected to transmit one or more product ions to a detector that measures the product ion signal. The observed m/z ratio (and may also referred to as “mass data”) of a parent (or precursor) ion and its corresponding product (or daughter) ion is a product ion transition. This ion transition may also be referred to as a precursor-product ion transition or a product-daughter ion transition. In a multiple reaction monitoring (“MRM”) workflow, two or more transitions are monitored, each corresponding to a different fragment or product ion. For example, the parent ion of
morphine is 286, and the most intense ions created by the fragmentation of 286 are 201, 181, and 165. As such, the three product ion transitions for morphine are 286 —> 201, 286 —> 181, and 286 —►165.
[050] In other exemplary methods, at least two product ion transitions are monitored, alternatively at least three product ion transitions are monitored, alternatively at least four product ion transitions are monitored, alternatively at least five product ion transitions are monitored, alternatively at least six product ion transitions are monitored, alternatively at least seven product ion transitions are monitored, alternatively at least eight product ion transitions are monitored, alternatively at least nine product ion transitions are monitored, alternatively at least ten product ion transitions are monitored. In some exemplary methods, the product ion has an intensity and/or abundance of about 100%. In some exemplary methods, the product ion is the most intense and/or abundant isotope of the at least one analyte.
[051] In an isotopic multiple reaction monitoring (“Isotopic MRM”), the workflow utilizes the ion transitions based on the natural isotopic abundance of analytes. This ion transition may also be referred to as a precursor-isotopic ion transition or isotopic ion transition. For example, there are two stable isotopes of chlorine; chlorine 35 (75.8 % natural abundance) and chlorine 37 (24.2 % natural abundance). In general, each natural isotopic ion’s relative abundance value is different from another in a proportionally decreasing fashion. For example, the intensity and/or abundance of the isotopic ion is less than about 100%, alternatively less than about 50%, alternatively less than about 25%, alternatively less than about 15%, alternatively less than about 10%, alternatively less than about 5% than a precursor and/or the product ion. The natural isotopic daughter ion acts as an internal standard, allowing for quantification of the analyte without requiring the addition of a calibrant or stable-isotope labeled analyte.
[052] In other exemplary methods, at least two isotopic ion transitions are monitored, alternatively at least three isotopic ion transitions are monitored, alternatively at least four isotopic ion transitions are monitored, alternatively at least five isotopic ion transitions are monitored, alternatively at least six isotopic ion transitions are monitored, alternatively at least seven isotopic ion transitions are monitored, alternatively at least eight isotopic ion transitions
are monitored, alternatively at least nine isotopic ion transitions are monitored, alternatively at least ten isotopic ion transitions are monitored.
[053] The methods of this disclosure can be practiced using mass spectrometers single-stage mass spectrometers or that have the ability to select and fragment molecular ions, for example, tandem mass spectrometers, i.e., mass spectrometers that have two mass separators with an ion fragmentor disposed in the ion flight path between the two mass separators. Non-limiting examples of mass separators include, but are not limited to, quadrupoles, RF multipoles, ion traps, time-of-flight (TOF), and TOF in conjunction with a timed ion selector. Non-limiting examples of ion fragmentors include, but are not limited to, those operating on the principles of collision induced dissociation (CID, also referred to as collisionally assisted dissociation (CAD)), photoinduced dissociation (PID), surface induced dissociation (SID), post source decay, by interaction with an electron beam (e.g., electron induced dissociation (EID), electron capture dissociation (ECD)), interaction with thermal radiation (e.g., thermal/black body infrared radiative dissociation (BIRD)), post source decay, or combinations thereof.
[054] Non-limiting examples of a single-stage mass spectrometry system includes magnetic sector, quadrupole, time-of-flight (TOF), and ion traps. Non-limiting examples of tandem mass spectrometry systems for mass analysis include, but are not limited to, those which comprise one or more of a triple quadrupole, a quadrupole-linear ion trap (e.g., QTRAP® System), a quadrupole TOF (e.g., TripleTOF® System), and a TOF-TOF. In some non-limiting aspects, a mass analyzer is configured to perform a first mass analysis on the sample, wherein the first mass analysis is mass screening for an analyte of interest in the sample, and wherein if the analyte of interest is detected in the sample, the mass analyzer is configured to perform a second mass analysis, wherein the second mass analysis is a quantitative analysis.
[055] In an aspect, the sample may be transferred from the sample introduction device to the mass analyzer using transfer techniques generally known in the art such as, for example, techniques including a microinjector, a nano injector, an inkjet printer nozzle, an acoustic droplet ejector (ADE), a solid phase extraction system, or a liquid aspiration system. While the transferred volumes may vary, typical volumes of transferred solutions fall within a range of about 2.5 nL to about 500 nL.
[056] Non-limiting examples of the sample introduction device include a chromatography instrument (such as a high performance liquid chromatography (HPLC) instrument, an ultra high performance liquid chromatography instrument (UPLC), micro liquid chromatography, or nano liquid chromatography), microflow system, solid-phase extraction system, liquid-liquid extraction, protein precipitation, differential mobility spectrometer, a trap-and-elute workflow, an open port interface, or direct flow injection. In an aspect, the sample solution may be introduced to the ion source by acoustically ejecting the sample into a mobile phase at an open port interface (OPI) using the acoustic droplet ejector (ADE).
[057] In some aspects, the combination of open port interface (OPI) and acoustic droplet ejection (ADE) is referred to as Acoustic Ejection Mass Spectrometry (AEMS). Examples of acoustic ejection mass spectrometry systems for qualitative mass analysis include an Echo® MS System.
[058] It will further be appreciated that any number of additional elements can be included in the sample processing system including, for example, an ion mobility spectrometer (e.g., a differential mobility spectrometer for ion selection) that is disposed between the ionization chamber and the mass analyzer and is configured to separate ions based on their mobility through a drift gas in high- and low-fields rather than their mass-to-charge ratio. Additionally, it will be appreciated that the mass analyzer can comprise a detector that can detect the ions which pass through the mass analyzer and can, for example, supply a signal indicative of the number of ions per second that are detected.
[059] In an exemplary method, the first labeled isotopologue is an internal standard that is used for normalization. In a non-limiting example, normalization with first labeled isotopologue includes using the peak area of the parent or product ion of the first labeled isotopologue and the peak area of the parent or product ion of the analyte and/or the second labeled isotopologue to calculate a peak area ratio. The analyte and/or the second labeled isotopologue is then normalized using said peak area ratio. In some methods, the intensity difference between the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest may be used as a response factor for signal intensity normalization. In this method, the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest may be at the same concentration.
[060] The second labeled isotopologue (and any subsequent labeled isotopologue) may be used for the generation an internal calibration curve. The intensity, or area, of a product ion transition or isotopic ion transition depends on several factors including concentration, ease of ionization, and fragmentation efficiency. The peak areas for product ion transitions or isotopic ion transitions are integrated as measures of product ion or isotopic ion abundance and serve as the basis for quantitative comparisons. To quantify an analyte using product ion transitions or isotopic ion transitions, the signal intensity or relative abundance of the product ion and/or isotopic ion is compared to, for example, an internal calibration curve constructed using one or more labeled isotopologues and/or by calculating a ratio of at least one isotopic ion transition to the corresponding analyte, and quantifying the amount of the analyte in the sample using the calculated ratio. Depending on the analyte of interest, the calibration curve may be generated using at least one product ion transition, at least one isotopic ion transition, or a combination of both. The internal calibration curve may be constructed by using the natural isotopic abundance of one isotopologue, by using multiple differently labeled isotopologues of different concentrations, or combinations of these methods.
[061] In a non-limiting example, a calibration curve is generated for fentanyl. FIGs. 1A-1C depict structures of different isotopologues of fentanyl. FIG 1A is fentanyl-d5 (MW = 341.50), FIG. IB is fentanyl-13C6 (MW = 342.43), and FIG. 1C is fentanyl (MW = 336.47, no isotopic label). The unlabeled fentanyl is used to quantify the unknowns and either of the isotopologues could be used for an internal standard. To generate the calibration curve, the natural isotopic abundance of either one or both of the labeled isotopologues to generate a calibration curve with isotopic MRMs that do not interfere with the analyte or the internal standard MRM channel. FIG. 2 depicts an internal isotopic calibration curve according to an aspect of the disclosure. FIG. 3 depicts the peak intensities of an analyte of interest, an internal standard (a first labeled isotopologue), and high, middle, and low isotopic calibrants (generated from a second labeled isotopologue) according to an aspect of the disclosure.
[062] The calculated ratio may be used to calculate an isotopic dilution factor (“IDF”). This IDF may be used as a multiplier to compensate for abundance differences between the naturally occurring abundant isotopes and the corresponding analyte and/or precursor. In some aspects, the precursor is most abundant isotope. In some aspects, the isotope MRM conditions may be auto-
optimized. For example, the theoretical isotope intensity ratio of both precursor and isotopic ions, and the desired intensity level is used to choose the isotope MRM conditions. In a non-limiting example, the most abundant transition peak is the peak that is used to quantify the majority of the samples. The isotopic ion transition peak is a peak of lower abundance that can be used as a dilution factor. The factor difference between the quantifying transition and isotopic ion transition can be easily determined and applied to samples which require quantification using the isotopic ion transition.
[063] By adding a sample to the disclosed reaction mixture, sample preparation be performed in under 10 minutes, alternatively under 9 minutes, alternatively under 8 minutes, alternatively under 7 minutes, alternatively under 6 minutes, alternatively under 5 minutes, alternatively under 4 minutes, alternatively under 3 minutes, alternatively under 2 minutes, or alternatively under 1 minute. Additionally, the resulting sample preparation product can be used for both screening and definitive testing. The disclosed methods allow for simple sample preparation that can be performed manually (point of care application) or with automation (for large batches). Due to the presence of an internal calibration curve with an internal standard in the reagent, the screening test can now be classified as a semi-quantitative test which provides a user with a greater level of knowledge about each individual sample before the sample is quantitatively analyzed on the definitive testing platform. Additionally, the combination of internal calibration curve and internal standard for each individual sample ensures that matrix effects are neutralized. Comparing results from an unknown sample to an external calibration curve can often ignore sample matrix effects. In a non-limiting example, the use of the reaction mixture reduces matrix effects and at the same time desalts the sample. Furthermore, the use of internal calibration enables random access testing, enabling emergency testing and point of care testing with a mass spectrometer.
[064] In some aspects, there may be a kit included for carrying out the disclosed methods. The kit may include at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest and magnetic beads. The magnetic beads may include, but are not limited to, the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and
combinations thereof. In a non-limiting example, the first labeled isotopologue, second labeled isotopologue and magnetic beads are in a single reaction mixture. As shown in FIG. 4, the reaction mixture includes the first labeled isotopologue, second labeled isotopologue, ferromagnetic beads, and desalting beads. The single reaction mixture may also be housed in a container. Nonlimiting examples of suitable contains include, test tubes, centrifuge tubes, vials, cups, or bottles. In some aspects, the container is a sample plate, the sample plate comprising a plurality of sample wells. The sample wells may contain the sample which the reaction mixture is added to. Depending on the analysis desired, the sample wells may contain several different samples and/or calibrants.
EXAMPLES
[065] An equal amount of Phenomenex 100 ferromagnetic beads and mixed-phase micro-sized, paramagnetic desalting beads were suspended in a solution of 95/5 water/methanol. 500 ng/mL of fentanyl-d5, 500 ng/mL of norfentanyl-d5, 200 ng/mL of fentanyl-13Ce, and 200 ng/mL of norfentanyl-13Ce were added to the magnetic beads solution.
[066] The sample is collected using any specimen collection method know in the art. Urine samples can be collected according to the SAMHSA guidelines (Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention), available at https://www.samhsa.gov/sites/default/files/specimen-collection-handbook-2014.pdf. Urine specimens are typically submitted to certified laboratories within 24 hours after collection.
[067] 50 pL of the reaction mixture was added to 50 pL of the sample. Electromagnets were used to mix the sample mixture and a magnetic rack is used to pull the magnetic beads with to one side of the reaction vessel. The supernatant was removed and the magnetic beads were washed with 200 pL of di water and 65 pL to elute the desalted sample. Electromagnets were used to mix the sample mixture and a magnetic rack is used to pull the magnetic beads with to one side of the reaction vessel. 50 pL was the supernatant and 10 pL of water were added to an acoustic ejection mass spectrometry (AMES) 384- well plate. The plate was then shook on a planar rotator.
[068] Using AMES, and as shown in FIG. 5 the MRM transitions for fentanyl monitored were 327.25 — 188.14 (analyte of interest); 343.2 — 105.1 (internal standard); and 342.24 — 188.14,
343.25 —> 189.15, and 344.24 — > 190.15 (calibration curve). The MRM transitions for norfentanyl monitored were 233.16 — 84.08 (analyte of interest); 239.1 — 156.1 (internal standard); and 238.18 — 84.08, 240.18 — 84.08, and 240.18 —>85.08 (calibration curve). The peak areas for the three isotopic MRMs for fentanyl and norfentanyl were corrected with a response factor adjustment derived from the respective internals standards. These isotopic MRMs were also chosen so that they do not interfere with the internal standard.
[069] The analysis of samples with known concentrations of fentanyl and norfentanyl using AEMS with isotopologues for the internal standard and an internal calibration curve is shown in FIG. 6. The isotopologues used for the internal standard and the internal calibration curve generated peaks that were relatively of the same height for each particular transition. Analyte transitions produced variable peak height due to the different concentrations of the analyte within each sample. With AEMS, good quality, semi-quantitative results can be achieved in less than 8 minutes (FIG. 7). As shown in FIG. 8 and FIG. 9 the reproducibility for the internal standard isotopologue (FIG. 8) and the reproducibility for the isotopic transitions of the internal calibration isotopologue of fental-d5 at 100 ng/mL, 14.6 ng/mL, and 0.99 ng/mL (FIG. 9) were consistent throughout the run of over 100 unknown samples and quality control samples. A method comparison for fentanyl between the AEMS method and an LC-MS/MS reference method is shown in FIGs. 10A and 10B. In general, there was a positive correlation between the two methods, however, the correlation coefficient is relatively low. Additionally, FIG. 10B shows the percent difference chart for the comparison between the AEMS method and LC-MS/MS reference method. The results shown in FIG. 10A and FIG. 10B suggest that the present AEMS method is suitable for screening and semi-quantitative analysis, but is not suitable for use as a definitive quantitative analysis method. The samples prepared for analysis on the present AEMS method were then analyzed by an LC-MS/MS method with a gradient elution (FIGs. 11 A-l 1C). The LC-MS/MS method separated the components within the prepared sample on a chromatography column, across a liquid chromatography gradient. FIG. 11 A shows fentanyl and norfentanyl isotopic MRMs separated from one another while FIG. 1 IB and FIG. 11C show the detailed information of each isotopic MRM for norfentanyl (FIG. 1 IB) and fentanyl (FIG. 11C).
[070] While the present disclosure has been described with reference to certain aspects, it will be understood by those skilled in the art that various changes may be made and equivalents may
be substituted without departing from the scope of the present disclosure or appended claims. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the present disclosure without departing from its scope. Therefore, it is intended that the present disclosure not be limited to the particular aspects disclosed, but that the present disclosure will include all aspects falling within the scope of the appended claims.
[071 ] All patents, patent applications, publications, and descriptions mentioned above are herein incorporated by reference in their entirety.
Claims
1. A method for quantifying at least one analyte in a sample by mass analysis, the method comprising: adding a sample comprising an analyte of interest to a reaction mixture, the reaction mixture comprising at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, ionizing the resulting mixture, monitoring, by mass spectrometry, at least one parent ion and/or at least one fragment ion of the analyte of interest, the first labeled isotopologue and/or the second labeled isotopologue, wherein the at least one fragment ion is selected from the group consisting of a product ion, an isotopic ion, a product ion transition, and an isotopic ion transition; normalizing using the first labeled isotopologue; determining intensity and/or using natural isotopic abundance of at least one parent ion and at least one fragment ion of the second labeled isotopologue; generating an internal calibration curve based at least one product ion transition and/or at least one isotopic ion transition of the second labeled isotopologue; and quantifying the at least one analyte present in the sample using the calibration curve.
2. The method of claim 1, wherein the first labeled isotopologue is used as an internal standard.
3. The method of any one of the preceding claims, wherein the reaction mixture comprises at least a third labeled isotopologue, alternatively at least a fourth labeled isotopologue, alternatively at least a fifth labeled isotopologue.
4. The method of claim 3, wherein the second labeled isotopologue, third labeled isotopologue, fourth labeled isotopologue, and/or fifth labeled isotopologue is used to generate an internal calibration curve.
5. The method of any one of the preceding claims, wherein the first labeled isotopologue and second labeled isotopologue are labeled with at least one isotopic atom.
6. The method of claim 5, wherein the at least one isotopic atom is deuterium, carbon-13, nitrogen-15, or oxygen-18.
7. The method of any one of the preceding claims, wherein the isotopic atom of the first labeled isotopologue and the isotopic atom of the second labeled isotopologue are different.
8. The method of any one of the preceding claims, wherein the normalization with first labeled isotopologue further comprises: using peak area of the parent or product ion of the first labeled isotopologue and peak area of the parent or product ion of the analyte and/or the second labeled isotopologue to calculate a peak area ratio.
9. The method of any one of the preceding claims, wherein the product ion transition has an intensity and/or abundance of about 100%.
10. The method of claim 9, wherein the product ion transition is the most intense and/or abundant isotope of the at least one analyte.
11. The method of claim 9 or claim 10, wherein the intensity and/or abundance of the isotopic ion transition is less than about 100%, alternatively less than about 50%, alternatively less than about 25%, alternatively less than about 15%, alternatively less than about 10%, alternatively less than about 5% than a precursor and/or the product ion transition.
12. The method of any one of the preceding claims, wherein determining the intensity and/or abundance of the at least one product ion transition and/or isotopic ion transition comprises obtaining mass spectrum data corresponding to the at least one product ion transition and/or isotopic ion transition.
13. The method of any one of the preceding claims, wherein at least two analytes are quantified, alternatively at least three analytes are quantified, alternatively at least four analytes are quantified, alternatively at least five analytes are quantified, alternatively at least six analytes are quantified, alternatively at least seven analytes are quantified, alternatively at least eight
analytes are quantified, alternatively at least nine analytes are quantified, alternatively at least ten analytes are quantified.
14. The method of any one of the preceding claims, wherein at least two product ion transitions are monitored, alternatively at least three product ion transitions are monitored, alternatively at least four product ion transitions are monitored, alternatively at least five product ion transitions are monitored, alternatively at least six product ion transitions are monitored, alternatively at least seven product ion transitions are monitored, alternatively at least eight product ion transitions are monitored, alternatively at least nine product ion transitions are monitored, alternatively at least ten product ion transitions are monitored.
15. The method of any one of the preceding claims, wherein intensity difference between the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are used as a response factor for signal intensity normalization.
16. The method of claim 15, wherein the first labeled isotopologue and/or second labeled isotopologue and the analyte of interest are at the same concentration.
17. The method of any one of the preceding claims, wherein at least two isotopic ion transitions are monitored, alternatively at least three isotopic ion transitions are monitored, alternatively at least four isotopic ion transitions are monitored, alternatively at least five isotopic ion transitions are monitored, alternatively at least six isotopic ion transitions are monitored, alternatively at least seven isotopic ion transitions are monitored, alternatively at least eight isotopic ion transitions are monitored, alternatively at least nine isotopic ion transitions are monitored, alternatively at least ten isotopic ion transitions are monitored.
18. The method of any one of the preceding claims, wherein the method further comprises: using the intensity and/or abundance of the at least one product ion transition and/or the at least one isotopic ion transition of the second labeled isotopologue to calculate a ratio of the at least one product ion transition and/or the at least one isotopic ion transition to the product and/or precursor, and using the calculated ratio to calculate an isotopic dilution factor (IDF), wherein the IDF is used as a multiplier to compensate for high concentrations of analyte of interest.
19. The method of any one of the preceding claims, wherein the reaction mixture further comprises magnetic beads.
20. The method of claim 19, wherein the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand- conjugated magnetic beads, enzyme- conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
21. The method of claim 20, wherein the mixed- phase magnetic beads are selected from C4 magnetic beads, C8 magnetic beads, Cl 2 magnetic beads, Cl 8 magnetic beads, cyanopropyl magnetic beads, phenyl magnetic beads, diphenyl magnetic beads, and combinations thereof.
22. The method of claim 20 or claim 21, wherein the sample is desalted using the mixed- phase magnetic beads.
23. The method of claim 20, wherein the enzyme-conjugated magnetic beads are conjugated with trypsin, chymotrypsin, glucuronidase, or combinations thereof.
24. The method of claim 23, wherein the sample is digested and/or hydrolyzed using the enzyme-conjugated magnetic beads.
25. The method of any one of claims 19-24, wherein the sample is eluted from the magnetic beads prior to being ionized.
26. The method of any one of the preceding claims, wherein the mass spectrometry is conducted using a mass analyzer.
27. The method of claim 26, wherein the mass analyzer is coupled to a sample introduction device.
28. The method of claim 27, wherein the sample introduction device comprises an acoustic droplet ejector (ADE), a solid phase extraction system, liquid-liquid extraction, protein
precipitation, a liquid aspiration system, a microinjector, a nanoinjector, an inkjet printer nozzle, a chromatography instrument, microflow system, solid phase extraction system, differential mobility spectrometer, a trap-and- elute workflow, an open port interface, or direct flow injection.
29. The method of claim 28, wherein the sample introduction comprises acoustically ejecting the liquid sample into a mobile phase at an open port interface (OPI) using the acoustic droplet ejector (ADE).
30. The method of claim 28, wherein the chromatography instrument is a high performance liquid chromatography (HPLC) instrument, an ultra high performance liquid chromatography instrument (UPLC), Micro liquid chromatography, or Nano liquid chromatography.
31. The method of any one of claims 26-30, wherein the mass analyzer is configured to perform a first mass analysis on the sample, wherein the first mass analysis is mass screening for an analyte of interest in the sample, and wherein if the analyte of interest is detected in the sample, the mass analyzer is configured to perform a second mass analysis, wherein the second mass analysis is a quantitative analysis.
32. The method of any one of claims 26-31, wherein the mass analyzer is a tandem mass spectrometer.
33. The method of claim 31 or claim 32, wherein the first mass analysis is performed using a first mass analyzer and the second mass analysis is performed using a second mass analyzer.
34. The method of any one of claims 31-33, wherein the first mass analyzer is a single-stage mass spectrometer or a tandem mass spectrometer.
35. The method of claim 34, wherein the single-stage mass spectrometer is selected from the group consisting of magnetic sector, quadrupole, time-of-flight (TOF), and ion traps.
36. The method of any one of claims 33-35, wherein the second mass analyzer is a tandem mass spectrometer.
37. The method of any one of claims 32-36, wherein the tandem mass spectrometer is selected from the group consisting of a triple quadrupole, a quadrupole-linear ion trap, a quadrupole TOF, and a TOF-TOF.
38. The method of any one of the preceding claims, wherein the sample is a biological sample.
39. The method of claim 38, wherein the biological sample is selected from the group consisting of urine, blood, oral fluid, plasma, tissue, bone marrow, and tumor samples.
40. The method of any one of the preceding claims, wherein the method is used in a clinical analysis workflow.
41. The method of claim 40, wherein the clinical analysis is used to screen for drugs of abuse, peptide markers for disease states, and/or peptides from proteins and/or analytes of interest.
42. The method of claim 41, wherein the drugs of abuse are selected from the group consisting of amphetamines, methamphetamines, benzodiazepines, barbiturates, marijuana, cocaine, PCP, methadone, opioids (narcotics), fentanyl, norfentanyl, gabapentin, and pregabalin.
43. A kit for quantifying at least one analyte in a sample by mass analysis, the kit comprising: at least a first labeled isotopologue and a second labeled isotopologue of the least one analyte of interest, and magnetic beads.
44. The kit of claim 43, wherein the magnetic beads are selected from the group consisting of mixed-phase magnetic beads, affinity ligand-conjugated magnetic beads, enzyme-conjugated magnetic beads, ion exchange magnetic beads, ferromagnetic beads, paramagnetic beads, superparamagnetic beads, and combinations thereof.
45. The kit of claim 44, wherein the kit comprises mixed-phase magnetic beads, enzyme- conjugated magnetic beads and ferromagnetic beads.
46. The kit of any one of claims 43 to 45, wherein the first labeled isotopologue, second labeled isotopologue and magnetic beads are in a single reaction mixture.
47. The kit of claim 46, wherein the single reaction mixture is added to a sample comprising an analyte to be quantified.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263407514P | 2022-09-16 | 2022-09-16 | |
US63/407,514 | 2022-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024057238A1 true WO2024057238A1 (en) | 2024-03-21 |
Family
ID=88237756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/059103 WO2024057238A1 (en) | 2022-09-16 | 2023-09-13 | Single tube sample preparation and calibration for both screening and quantification of analytes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024057238A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3004861A1 (en) * | 2013-06-07 | 2016-04-13 | Pierce Biotechnology, Inc. | Absolute quantitation of proteins and protein modifications by mass spectrometry with multiplexed internal standards |
US20220099637A1 (en) * | 2018-12-04 | 2022-03-31 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
US11442046B2 (en) * | 2017-01-31 | 2022-09-13 | Roche Diagnostics Operations, Inc. | Reagent for mass spectrometry |
-
2023
- 2023-09-13 WO PCT/IB2023/059103 patent/WO2024057238A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3004861A1 (en) * | 2013-06-07 | 2016-04-13 | Pierce Biotechnology, Inc. | Absolute quantitation of proteins and protein modifications by mass spectrometry with multiplexed internal standards |
US11442046B2 (en) * | 2017-01-31 | 2022-09-13 | Roche Diagnostics Operations, Inc. | Reagent for mass spectrometry |
US20220099637A1 (en) * | 2018-12-04 | 2022-03-31 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11988670B2 (en) | Integrated sample processing system with multiple detection capability | |
US11300559B2 (en) | Vitamin B2 detection by mass spectrometry | |
US20220349897A1 (en) | Amyloid beta detection by mass spectrometry | |
Chong et al. | Clinical mass spectrometry in the bioinformatics era: a Hitchhiker’s guide | |
EP2021805A2 (en) | Expression quantification using mass spectrometry | |
US8614418B2 (en) | Methods for detecting catecholamines by mass spectrometry | |
WO2024057238A1 (en) | Single tube sample preparation and calibration for both screening and quantification of analytes | |
CN113330314A (en) | Automated sample workflow for LC-MS based HbA1c measurement with respect to intact protein levels | |
US8497079B2 (en) | Glucagon detection and quantitation by mass spectrometry | |
WO2023073587A1 (en) | Ultra high throughput screening combined with definitive testing in a single sample preparation step | |
EP3654032B1 (en) | Disease detection method | |
WO2023073588A1 (en) | Utilizing natural isotopic abundance of compounds to extend the dynamic range of an instrument | |
US20190285594A1 (en) | Methods for detecting chromogranin a by mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23783027 Country of ref document: EP Kind code of ref document: A1 |